BETHESDA, Md., Feb. 13, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD gives a Keynote presentation describing in vitro and in vivo efficacy of its novel tumor-specific ...
It is estimated that one-third of the 50 million people worldwide with epilepsy are resistant to anti-seizure medications. These patients, having drug-resistant epilepsy, have limited treatment ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
In today’s crowded, cost‑pressured pharma landscape, even proven brands struggle to stay on forecast. Missed patients, prescriber inertia, and fragmented execution mean opportunity is often not lost, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results